Abstract
Rates of reduced vancomycin susceptibility (RVS) among isolates of methicillin-susceptible Staphylococcus aureus (MSSA), especially methicillin-resistant S. aureus (MRSA), have increased. Although vancomycin remains the therapeutic mainstay for MRSA, clinical response to vancomycin has been compromised by RVS among our hospital clones. Laboratories need simple procedures to detect these organisms. Whilst routine disc or MIC susceptibility testing is not reliable, some useful screening procedures are available.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
